Meta-analysis Of Plasma MicroRNA As A Potential Diagnostic Marker For Glioma

Objective:Glioma is the most common malignant tumor in the brain.We hope to determine the accuracy of differentially expressed plasma miRNAs in the diagnosis of glioma by systematically analyzing the diagnostic value of plasma microRNAs(mi RNAs)for gliomas.Methods:Through computer searches such as PUB-MED,Medline,Cochrane,CNKI,Wanfang,etc.,a meta-analysis of the research on plasma mi RNA diagnosis of gliomas in recent years was collected.The two researchers studied in detail the included literature and collected data for comparison.The core data includes the author,number of years,true positives(tp),false positives(fp),and false negatives(fn),true negatives(ture negatives,tn).Quality assessments were evaluated using QUADAS-2 for each of the included studies.Use revman 5.3 to develop quality tables,risk bias items,and applicability summary graphs.The midas analysis module in stata 12.0 was used to analyze the data of diagnostic experiments to understand the heterogeneity and publication bias.The sensitivity,specificity and positive likelihood ratio of each study were calculated.(PLR)and Negative Likelihood Ratio(NLR).Selecting the corresponding effect module and merging the analysis data yielded a comprehensive receiver operating curve(SROC)for comprehensive analysis of the diagnostic potential and value of miRNAs.Results:Through computer-assisted manual search,we collected 143 articles and excluded articles that did not meet the standards.This study included a total of 9 articles,involving660 patients with gliomas and 459 non-glioma patients in the control group.After careful reading of the literature,the QUADAS-2 quality assessment tool on reman 5.3 was used to evaluate the main case selection,evaluation experiment,gold standard,case procedure and progress(clinical applicability evaluation).Each study was conducted.Above the median score,the risk of bias and applicability risk of the gold standard was found to be the highest,and the risk of selection bias and the risk of applicability were the lowest.After statistics,the data confirmed the diagnostic value of plasma miRNAs for gliomas,with a combined sensitivity of 0.865(95% CI: 0.795-0.914),a combined specificity of 0.919(95% CI: 0.828-0.964),and a positive likelihood ratio(PLR)10.646(95% CI: 4.775-23.736),Negative Likelihood Ratio(NLR)0.147(95% CI: 0.093-0.232),Diagnostic Odds Ratio(DOR)72.571(95% CI: 24.483-215.112).Data from the forest map of the pooled data showed that the sensitivity Q test was p<0.01,the I2 statistic was90.15,the specific Q test was p<0.01,and the I2 statistic was 82.12,demonstrating that the sensitivity and specificity of the studies were statistically significant.Meaning,but more heterogeneous.Based on the receiver operating curve(SROC),the area under the curve(AUC)was 0.94(95% CI: 0.92-0.96),demonstrating that plasma miRNA may be a valuable molecular marker.After group statistics,the specificity and sensitivity of miRNA combinations in the diagnosis of gliomas are higher.Conclusion:Plasma miRNAs have a great potential in the diagnosis of gliomas,and combined miRNAs have higher accuracy than single miRNAs and may become an effective non-invasive biological marker for gliomas.